IGC Pharma (NYSEAMERICAN:IGC) Given Buy Rating at Ascendiant Capital Markets

Ascendiant Capital Markets reiterated their buy rating on shares of IGC Pharma (NYSEAMERICAN:IGC) in a research report released on Friday morning, Benzinga reports. The firm currently has a $3.25 price objective on the construction company’s stock.

Separately, StockNews.com initiated coverage on IGC Pharma in a research report on Monday, May 6th. They set a sell rating on the stock.

IGC Pharma Stock Performance

Shares of IGC Pharma stock opened at $0.41 on Friday. The firm has a market capitalization of $27.06 million, a PE ratio of -1.56 and a beta of 1.51. The company has a quick ratio of 0.86, a current ratio of 1.85 and a debt-to-equity ratio of 0.02. IGC Pharma has a fifty-two week low of $0.25 and a fifty-two week high of $0.91.

IGC Pharma Company Profile

IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.